autologous anti-CD22 CAR-expressing T cells SCRI-CAR22v2

A preparation of autologous human T lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the autologous anti-CD22 CAR-expressing T cells SCRI-CAR22v2 express anti-CD22-CAR on their cell surfaces and bind to the CD22 antigen on tumor cell surfaces leading to lysis of CD22-expressing B cells. CD22, a B-lineage-restricted, transmembrane phosphoglycoprotein, is expressed on malignant B cells.